Microdosing and drug development: Past, present and future

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 7, 2013, Pages 817-834

  Lappin, Graham ^a   Noveck, Robert ^b   Burt, Tal ^b  

^a UNIVERSITY OF LINCOLN   (United Kingdom)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Dose linearity; Microdosing; Pharmacokinetic prediction; Pharmacokinetics; Phase 0

Indexed keywords

ATENOLOL; CAFFEINE; CARBAMAZEPINE; CELIPROLOL; CLARITHROMYCIN; DIAZEPAM; DIGOXIN; DIPHENHYDRAMINE; ENALAPRIL; FEXOFENADINE; FOSDEVIRINE; LOSARTAN; METFORMIN; METOPROLOL; MIDAZOLAM; NICARDIPINE; PARACETAMOL; PHENAZONE; PHENOBARBITAL; PROPAFENONE; QUINIDINE; RALTEGRAVIR; SUMATRIPTAN; TELMISARTAN; TENOFOVIR; TOLBUTAMIDE; UNINDEXED DRUG; VERAPAMIL; WARFARIN; ZIDOVUDINE;

AREA UNDER THE CURVE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG MICRODOSE; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; LIVER CLEARANCE; NONHUMAN; PEER REVIEW; PLASMA CONCENTRATION-TIME CURVE; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GUIDELINES AS TOPIC; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84879249429     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.786042     Document Type: Review

References (99)

1. Garner RC. Accelerator mass spectrometry in pharmaceutical research and development-a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 2000;1(2):205-13
2. Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2003;2(3):233-40. (Pubitemid 37361669)
3. Lappin G, Garner RC. A review of human phase 0 and microdosing clinical trials following the US food and drug administration exploratory investigational new drug studies guidance. In J Pharm Med 2006;30(3):159-65 (Pubitemid 44166665)
4. Oosterhuis B. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development. Bioanalysis 2010;2(3):377-9
5. Boyd RA, Lalonde RL. Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact? Clin Pharmacol Ther 2007;81(1):24-6 (Pubitemid 46050861)
6. Rowland M, Benet LZ, Lead PK. Commentary: phRMA PISC-prediction of human pharmacokinetics. J Pharm Sci 2011;100(10):4047-9 . Commentary and summary of PhRMA-sponsored study examining PK predictive modelling.
7. Kummar S, Kinders R, Gutierrez ME, et al. Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies. J Clin Oncol 2009;27(16):2705-11
8. ICH Topic M3 Note for Guidance on non-clinical safety pharmacology studies for human pharmaceuticals CPMP/ICH/286/95; 2009
9. Bertino JS Jr, Greenberg HE, Reed MD. American college of clinical pharmacology position statement on the use of microdosing in the drug development process. J Clin Pharmacol 2007;47(4):418-22 (Pubitemid 46465964)
10. Rowland M. Microdosing: a critical assessment of human data. J Pharm Sci 2012;101(11):4067-74.
11. Yamane N, Igarashi A, Kusama M, et al. Cost-Effectiveness Analysis of Microdose Clinical Trials in Drug Development. Drug Metab Pharmacokinet 2013;In press Article ID: DMPK-12-RG-044
12. EMEA Position Paper on Non-clinical Safety Studies to Support Clinical Trials with a Single Microdose. CPMP/SWP/2599; 2004
13. Food and Drug Administration US Department of Health and Human Services Guidance for Industry Investigators and Reviewers. Exploratory IND Studies (January 2006)
14. Pharmaceutical and Medical Safety Bureau, Tokyo. Microdose clinical studies. Ministry of Health, Labor and Welfare, Japan; 2008
15. Calvert AH, Plummer R. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials. Clin Cancer Res 2008;14(12):3664-9
16. Lappin G, Wagner C, Langer O, et al. New Ultrasensitive detection technologies and techniques for use in microdosing studies. Bioanalysis 2009;1(2):357-66
17. Wagner CC, Simpson M, Zeitlinger M, et al. A Combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C-and 11C-labelled verapamil. Clin Pharmacokinet 2010;50(2):111-20
18. Wagner CC, Muller M, Lappin G, Langer O. Positron emission tomography for use in microdosing studies. Curr Opin Drug Discov Devel 2008;11(1):104-10
19. Sugiyama Y. Effective use of microdosing and Positron Emission Tomography (PET) studies on new drug discovery and development. Drug Metab Pharmacokinet 2009;24(2):127-9
20. Barker J, Garner RC. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun Mass Spectrom 1999;13(4):285-93 (Pubitemid 29101097)
21. Salehpour M, Possnert G, Bryhni H. Subattomole sensitivity in biological accelerator mass spectrometry. Anal Chem 2008;80(10):3515-21 (Pubitemid 351705849)
22. Comezoglu SN, Ly VT, Zhang D, et al. Biotransformation profiling of [(14)C] ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). Drug Metab Pharmacokinet 2009;24(6):511-22
23. Ings R. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge. Bioanalysis 2009;1(17):1293-305
24. Rowland M. Interview: interview with Professor Malcolm Rowland. Bioanalysis 2010;2(3):385-91
25. Lappin G, Rowland M, Garner RC. The use of isotopes in the determination of absolute bioavailability of drugs in humans. Expert Opin Drug Metab Toxicol 2006;2(3):419-27 (Pubitemid 46141407)
26. Strong JM, Dutcher JS, Lee WK, Atkinson AJ Jr. Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method. Clin Pharmacol Ther 1975;18(5 Pt 1):613-22
27. Bae SK, Shon JH. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials. Arch Pharm Res 2011;34(11):1789-98
28. Gu H, Wang J, Aubry AF, et al. Calculation and mitigation of isotopic interferences in liquid chromatography-mass spectrometry/mass spectrometry assays and its application in supporting microdose absolute bioavailability studies. Anal Chem 2012;84(11):4844-50
29. Boddy AV, Sludden J, Griffin MJ, et al. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin Cancer Res 2007;13(14):4164-9 (Pubitemid 47105979)
30. Sparreboom A. Unexplored pharmacokinetic opportunities with microdosing in oncology. Clin Cancer Res 2007;13(14):4033-4 (Pubitemid 47105961)
31. Lappin G, Kuhnz W, Jochemsen R, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006;80(3):203-15. (Pubitemid 44313903)
32. Sarapa N, Hsyu PH, Lappin G, Garner RC. The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 2005;45(10):1198-205 (Pubitemid 41361920)
33. Lappin G. Microdosing: current and the future. Bioanalysis 2010;2(3):509-17
34. The nobel prize in chemistry 1943 George de Hevesy. Available from: http://www.nobelprize.org/nobel-prizes/chemistry/laureates/1943/
35. Ostenfeld T, Beaumont C, Bullman J, et al. Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A. Br J Clin Pharmacol 2012;74(6):1033-44
36. Maeda K, Sugiyama Y. Novel strategies for microdose studies using non-radiolabeled compounds. Adv Drug Deliv Rev 2011;63532-8
37. Sun L, Li H, Willson K, et al. Ultrasensitive Liquid Chromatography- Tandem Mass Spectrometric Methodologies for Quantification of Five HIV-1 Integrase Inhibitors in Plasma for a Microdose Clinical Trial. Anal Chem 2012;84(20):8614-21
38. Zhou XJ, Garner RC, Nicholson S, et al. Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects. J Clin Pharmacol 2009;49(12):1408-16.
39. Yamane N, Tozuka Z, Kusama M, et al. Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose clinical studies. Pharm Res 2011;28(8):1963-72
40. Croft M, Keely B, Morris I, et al. Predicting drug candidate victims of drug-drug interactions, using microdosing. Clin Pharmacokinet 2012;51(4):237-46.
41. Lappin G, Simpson M, Shishikura Y, Garner C. High-performance liquid chromatography accelerator mass spectrometry: correcting for losses during analysis by internal standardization. Anal Biochem 2008;37893-5
42. Young G, Ellis WJ. AMS in drug development at GSK. Nucl Instruments Methods Phys Res 2007;B259:752-7 (Pubitemid 46726823)
43. Affinium. Affinium Pharmaceuticals, Ltd. Announces first patient dosed with oral AFN-1252 in a phase 2 clinical trial for acute bacterial skin & skin structure infections. 2012. Available from: http://www.afnm.com/news/ affinium-news-020112.htm.
44. Wang JL, Aston K, Limburg D, et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: the three microdose candidates. Bioorg Med Chem Lett 2010;20(23):7164-8
45. Kuwano K, Hashino A, Asaki T, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl) (isopropyl)amino]butoxy]-N-(methylsulfonyl) acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther 2007;322(3):1181-8 (Pubitemid 47295780)
46. Lappin G, Garner C. The utility of microdosing over the past 5 years. Expert Opin Drug Metab Toxicol 2008;4(12):1499-506
47. Levy G, Mager DE, Cheung WK, Jusko WJ. Comparative pharmacokinetics of coumarin anticoagulants L: physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci 2003;92(5):985-94 (Pubitemid 36523444)
48. Lappin G, Shishikura Y, Jochemsen R, et al. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur J Pharm Sci 2011;43:141-50.
49. Tang H, Mayersohn M. A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry. J Pharm Sci 2006;95(8):1783-99 (Pubitemid 44229585)
50. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J 2011;13(4):519-47 . Publication of the BDDCS drug classification system.
51. Zhao P, Rowland M, Huang SM. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 2012;92(1):17-20
52. Beaumont K, Smith DA. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr Opin Drug Discov Devel 2009;12(1):61-71
53. Jones RD, Jones HM, Rowland M, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci 2011;100(10):4074-89
54. Poulin P, Jones HM, Jones RD, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 1: goals, properties of the PhRMA dataset, and comparison with literature datasets. J Pharm Sci 2011;100(10):4050-73
55. Poulin P, Jones RD, Jones HM, et al. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. J Pharm Sci 2011;100(10):4127-57
56. Ring BJ, Chien JY, Adkison KK, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci 2011;100(10):4090-110
57. Vuppugalla R, Marathe P, He H, et al. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J Pharm Sci 2011;100(10):4111-26
58. Maeda K, Ikeda Y, Fujita T, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther 2011;90(4):575-81
59. Tachibana T, Kato M, Sugiyama Y. Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values. Pharm Res 2012;29(3):651-68
60. Ieiri I, Doi Y, Maeda K, et al. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol 2011
61. Ieiri I, Fukae M, Maeda K, et al. Pharmacogenomic/pharmacokinetic assessment of a four-probe cocktail for CYPs and OATPs following oral microdosing. Int J Clin Pharmacol Ther 2012;50(10):689-700
62. Turteltaub KW, Dingley KH, Curtis KD, et al. Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses. Cancer Lett 1999;143(2):149-55 (Pubitemid 29392948)
63. Turteltaub KW, Mauthe RJ, Dingley KH, et al. MeIQx-DNA adduct formation in rodent and human tissues at low doses. Mutat Res 1997;376(1-2):243-52 (Pubitemid 27248608)
64. Lappin G, Warrington S, Honeybourne D, et al. Concentrations of AR-709 in plasma and key compartments of the lungs after microdosing. Paper presented at the Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, USA; 2007
65. Vuong LT, Ruckle JL, Blood AB, et al. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. J Pharm Sci 2008;97(7):2833-43
66. Chen J, Flexner C, Liberman RG, et al. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of Zidovudine triphosphate in a microdosing study. J Acquir Immune Defic Syndr 2012;61(5):593-9
67. Chen J, Garner RC, Lee LS, et al. Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. Clin Pharmacol Ther 2010;88(6):796-800
68. Chen J, Seymour M, Lee L, et al. Accelerator Mass Spectrometry: A New Way to Measure Intracellular NRTI Triphosphates. 16th Conference on Retroviruses and Opportunistic Infections; San Francisco, USA; 2009
69. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992;65(2):287-91
70. Parlato C, Barbarisi M, Moraci M, Moraci A. Surgery, radiotherapy and temozolomide in treating high-grade gliomas. Front Biosci 2006;11:1280-3 (Pubitemid 43253420)
71. Martin EA, Brown K, Gaskell M, et al. Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res 2003;63(23):8461-5 (Pubitemid 37549502)
72. Vuong LT, Blood AB, Vogel JS, et al. Applications of accelerator MS in pediatric drug evaluation. Bioanalysis 2012;4(15):1871-82.
73. Harrison A, Gardner I, Hay T, et al. Case studies addressing human pharmacokinetic uncertainty using a combination of pharmacokinetic simulation and alternative first in human paradigms. Xenobiotica 2012;42(1):57-74
74. FDA. Food and Drug Administration US Department of Health and Human Services Guidance for Industry Safety Testing of Drug Metabolites. 2008
75. Garner RC. Less is more: the human microdosing concept. Drug Discov Today 2005;10(7):449-51
76. Chan E, McLachlan AJ, Pegg M, et al. Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol 1994;37(6):563-9 (Pubitemid 24197150)
77. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989;16(6):337-64 (Pubitemid 19167715)
78. Lappin G, Shishikura Y, Jochemsen R, et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci 2010;40125-31.
79. Yamazaki A, Kumagai Y, Yamane N, et al. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. J Clin Pharm Ther 2010;35(2):169-75
80. Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect 1991;19(Suppl A):29-37
81. Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31(5):291-4
82. Hollmann M, Brode E, Hotz D, et al. Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung 1983;33(5):763-70 (Pubitemid 13087997)
83. Albert KS, Sedman AJ, Wilkinson P, et al. Bioavailability studies of acetaminophen and nitrofurantoin. J Clin Pharmacol 1974;14(5-6):264-70
84. Viswanathan CT, Booker HE, Welling PG. Pharmacokinetics of phenobarbital following single and repeated doses. J Clin Pharmacol 1979;19(5-6):282-9 (Pubitemid 9192982)
85. Madan A, O'Brien Z, Wen J, et al. A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2008;67(3):288-98.
86. Zhou XJ, Pietropaolo K, Damphousse D, et al. Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects. Antimicrob Agents Chemother 2009;53(5):1739-46
87. Yamane N, Takami T, Tozuka Z, et al. Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma. Drug Metab Pharmacokinet 2009;24(4):389-403
88. Fredholm BB, Battig K, Holmen J, et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999;51(1):83-133 (Pubitemid 29113867)
89. Uchida S, Yamada H, Li XD, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006;46(11):1290-8 (Pubitemid 44564357)
90. Ieiri I, Nishimura C, Maeda K, et al. Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics 2011;21(8):495-505
91. Mahajan R, Parvez A, Gupta K. Microdose vs Therapeutic dose for evaluation of pharmacokinetic data: a comparative study. J Young Pharmacists 2009;28(1):290-4
92. Kusuhara H, Ito S, Kumagai Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011;89(6):837-44.
93. Maeda K, Takano J, Ikeda Y, et al. Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin Pharmacol Ther 2011;90(2):263-70
94. Friedman H, Greenblatt DJ, Peters GR, et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther 1992;52(2):139-50
95. Blyden GT, Greenblatt DJ, Scavone JM, Shader RI. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. J Clin Pharmacol 1986;26(7):529-33 (Pubitemid 16050179)
96. Mclean MA, Tam C-Y, Baratta MT, et al. accelerating drug development: methodology to support first-in-man pharmacokinetic studies by the use of drug candidate microdosing. Drug Dev Res 2007;6814-22
97. Ni J, Ouyang H, Aiello M, et al. Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. Pharm Res 2008;25(7):1572-82
98. Balani SK, Nagaraja NV, Qian MG, et al. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 2006;34(3):384-8 (Pubitemid 43290896)
99. Sandhu P, Vogel JS, Rose MJ, et al. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab Dispos 2004;32(11):1254-9 (Pubitemid 39410909)